Grok was a bit clearer in its summary and pretty much came up with the same results as CoPilot. I think the main difference between user research and clinical research is in the clinical trial they tend to run a cycle several times longer. And maybe that is due to a lot of these trials being sued to treat HIV patients. I can;t do much about the formatting of the tables, but I think you can read between the lines and get the gist of it. Or copy/paste into Excel and use a pipe delimiter to put the data into columns.
### Summary of Tesamorelin Posts on GLP1Forum
Based on the threads discussing Tesamorelin on GLP1Forum, users commonly report doses ranging from 1 mg to 2 mg per injection, with the 2 mg dose being the most frequent, often aligned with clinical recommendations. Frequency is typically daily or 5 days on/2 days off (e.g., Monday-Friday), to prevent desensitization or manage side effects like water retention. Durations vary widely, from as short as 1-4 weeks (often for initial trials) to 8-26 weeks or even 3-6 months for longer cycles, with some users cycling multiple times over years. Timing is predominantly at night or before bed, usually on an empty stomach (e.g., 2-3 hours after last meal), though a few mention morning or twice-daily dosing when stacked. Many users stack Tesamorelin with Ipamorelin (doses of 100-500 mcg), CJC-1295, or GLP-1 agonists like tirzepatide for synergy in fat loss, muscle preservation, or belly fat reduction. Reported benefits include visceral fat loss, improved body composition, and energy, but side effects like injection site stinging, water retention (2-6 lbs), increased hunger, or elevated pulse are common. Experiences are anecdotal, with some users adjusting doses based on tolerance (e.g., starting at 1 mg and ramping to 2 mg).
Here are links to the starting post of each relevant thread (conversation):
[archived internal link]
[archived internal link]
[archived internal link]
[archived internal link]
[archived internal link]
[archived internal link]
[archived internal link]
[archived internal link]
### Summary Chart from Reddit Posts and Other Websites (Excluding GLP1Forum)
The following table compiles user-reported and general dosing information from Reddit threads (primarily r/Peptides, r/PEDs, r/Testosterone, and r/PeptideGuide) and non-forum websites like WebMD (mentioned in discussions). Doses are commonly 1-2 mg, with daily or near-daily frequency, durations of weeks to months, and nighttime timing predominant. Stacking with Ipamorelin is frequent. These are anecdotal or general guidelines, not medical advice.
| Source | Dose Size | Frequency | Duration | Timing |
|--------|-----------|-----------|----------|--------|
| r/Peptides (Tesamorelin dosing) | 2 mg | Daily | Not specified | Night, empty stomach |
| r/Peptides (Tesamorelin, dosage, exercise) | Not specified (standard implied) | 1x daily, 5 on/2 off | Not specified | Before bed |
| r/Peptides (When to take tesamorelin) | 1 mg (with 250 mcg Ipamorelin) | Daily | Not specified | Night, 2-3 hours after dinner |
| r/PeptideGuide (Peptide Dosing Cheat Sheet) | 250-500 mcg (general peptide, but context includes Tesamorelin-like) | Daily | 4-8 weeks | Not specified |
| r/PEDs (Tesamorelin dosages) | 1 mg | Daily | 6 months (3 cycles) | Morning, upon waking |
| r/PeptideGuide (Q&A: Stacking Ipamorelin) | 1-2 mg | Daily, split into two doses | Not specified | Morning and before bed |
| r/Testosterone (Tesamorelin or ipamorelin fat loss) | 1-2 mg (with 100 mcg Ipamorelin) | Daily | Not specified | Not specified |
| r/Peptides (Tesamorelin And Ipamorelin Frequency) | 2 mg (with 250 mcg Ipamorelin) | Daily | Not specified | Night (Tesamorelin), morning and night (Ipamorelin) |
| r/AminoInsights (Complete Guide to Tesamorelin) | Not specified | Once daily, 5 on/2 off | 20-52 weeks | Before bed |
| r/Peptides (Tesamorelin dosing, older thread) | 1 mg | Daily, 5 on/2 off | Not specified | Night, 90 mins after last meal |
### Summary Chart from Research Papers, Clinical Trials, and Non-Commercial Sites
This table draws from authoritative sources like FDA labels, Mayo Clinic, NEJM, PMC, ScienceDirect, and MedlinePlus, focusing on clinical data without promotional content. Standard dosing is 2 mg daily subcutaneously, with durations from 12-52 weeks in trials, and timing often daily without strict hour specificity (though one trial specified morning). These are for approved uses like HIV-associated lipodystrophy; off-label use isn't covered.
| Source | Dose Size | Frequency | Duration | Timing |
|--------|-----------|-----------|----------|--------|
| Mayo Clinic (Tesamorelin subcutaneous) | 2 mg | Once daily | Determined by doctor | Not specified (around same time daily) |
| FDA Label (EGRIFTA®) | 2 mg | Once daily | 26-52 weeks (trials) | Not specified (subcutaneous, rotate sites) |
| NEJM (Metabolic Effects in HIV Patients) | 2 mg | Once daily | 26 weeks | Morning (6 a.m. to noon) |
| PMC (Safety in Type 2 Diabetes Patients) | 1-2 mg | Once daily | 12 weeks | Not specified |
| ScienceDirect (Tesamorelin Overview) | 0.5-2 mg (linear PK increase) | Once daily | Up to 12 months | Not specified |
| MedlinePlus (Tesamorelin Injection) | Not specified (standard implied) | Once daily | Not specified | Around same time every day |
